• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Amneal Pharmaceuticals Inc. (Amendment)

    4/24/24 6:03:48 AM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMRX alert in real time by email
    SC 13G/A 1 tm249671d1_sc13ga.htm SC 13G/A

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 4)*

     

    Amneal Pharmaceuticals, Inc.
    (Name of Issuer)
     
    Class A Common Stock, par value US$0.01 per share
    (Title of Class of Securities)
     
    03168L105
    (CUSIP Number)
     
    March 31, 2024
    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ¨ Rule 13d-1(b)

     

      x Rule 13d-1(c)

     

      ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    SCHEDULE 13G

     

    CUSIP No.      03168L105  

     

    1 Names of Reporting Persons
    Ambient Impact (HK) Limited
    2 Check the Appropriate Box if a Member of a Group (See Instructions)
    (a)  x
    (b)  ¨
    3 SEC Use Only
     
    4 Citizenship or Place of Organization
    Hong Kong

    Number of
    Shares
    Beneficially
    Owned by Each
    Reporting Person
    With:

     

    5 Sole Voting Power
    0
    6 Shared Voting Power
    7,558,303 (1)
    7 Sole Dispositive Power
    0
    8 Shared Dispositive Power
    7,558,303 (1)

    9 Aggregate Amount Beneficially Owned by Each Reporting Person
    7,558,303 (1)
    10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
    ¨
    11 Percent of Class Represented by Amount in Row (9)
    2.4% (2)
    12 Type of Reporting Person (See Instructions)
    CO

     

    (1)Number of shares is number of Class A Common Stock, par value US$0.01 per share ("Class A Common Stock") of Amneal Pharmaceuticals, Inc. (the “Issuer”).

     

    (2)

    This percentage is calculated based on 308,554,228 shares of Class A Common Stock outstanding as of March 11, 2024, as reported in the Issuer’s Schedule 14A filed on March 22, 2024.

     

    Page 2 of 7 

     

     

    SCHEDULE 13G

     

    CUSIP No.      03168L105  

     

    1 Names of Reporting Persons
    Fosun International Limited
    2 Check the Appropriate Box if a Member of a Group (See Instructions)
    (a)  x
    (b)  ¨
    3 SEC Use Only
     
    4 Citizenship or Place of Organization
    Hong Kong

    Number of
    Shares
    Beneficially
    Owned by Each
    Reporting Person
    With:

     

    5 Sole Voting Power
    0
    6 Shared Voting Power
    9,200,603 (1)
    7 Sole Dispositive Power
    0
    8 Shared Dispositive Power
    9,200,603 (1)

    9 Aggregate Amount Beneficially Owned by Each Reporting Person
    9,200,603 (1)
    10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
    ¨
    11 Percent of Class Represented by Amount in Row (9)
    3.0% (2)
    12 Type of Reporting Person (See Instructions)
    CO

     

    (1) Number of shares is number of Class A Common Stock of the Issuer. Fosun International Limited beneficially owns 9,200,603 shares of Class A Common Stock of the Issuer, consisting of (i) 7,558,303 shares of Class A Common Stock held directly by Ambient Impact (HK) Limited, a wholly-owned subsidiary of Fosun International Limited; and (ii) 1,642,300 shares of Class A Common Stock held directly by Fosun Atlas Capital SICAV RAIF S.C.S., a fund managed by a wholly-owned subsidiary of Fosun International Limited.

     

    (2) This percentage is calculated based on 308,554,228 shares of Class A Common Stock outstanding as of March 11, 2024, as reported in the Issuer’s Schedule 14A filed on March 22, 2024.

     

    Page 3 of 7 

     

     

    Item 1.  

     

    (a)Name of Issuer:

     

    Amneal Pharmaceuticals, Inc. 

     

    (b)Address of Issuer’s Principal Executive Offices:

     

    400 Crossing Boulevard

    Bridgewater, NJ 08807

     

    Item 2.  

     

    (a)Name of Person Filing:

     

    This Schedule 13G is filed by Ambient Impact (HK) Limited (“Ambient Impact”), a company organized under the laws of the Hong Kong Special Administrative Region of China (“Hong Kong”), and Fosun International Limited (“Fosun International”, together with Ambient Impact, the “Reporting Persons”), a company organized under the laws of Hong Kong.

     

    Ambient Impact is an indirectly wholly-owned subsidiary of Fosun International.

     

    (b)Address of Principal Business Office or, if None, Residence:

     

    The address of the principal business office for Ambient Impact is 5/F, Manulife Place, 348 Kwun Tong Road, Kowloon, Hong Kong. The address of the principal business office for Fosun International is Room 808, ICBC Tower, 3 Garden Road, Central, Hong Kong.

     

    (c)Citizenship:

     

    See Item 2(a)

     

    (d)Title of Class of Securities:

     

    Class A Common Stock of the Issuer

     

    (e)CUSIP No.:

     

    03168L105

     

    Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
         
    (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
         
    (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
         
    (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
         
    (e) ¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     

    (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
         
    (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
         
    (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
         
    (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
         
    (k) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

    Page 4 of 7 

     

     

    Item 4.Ownership.

     

      (a) See Item 9 of the cover pages to this Schedule 13G for the aggregate number of Class A Common Stock that are beneficially owned by each Reporting Person as of March 31, 2024.

     

      (b) See Item 11 of the cover pages to this Schedule 13G for the percentage of Class A Common Stock that are beneficially owned by each Reporting Person as of March 31, 2024.

     

      (c) See Items 5 through 8 of the cover pages to this Schedule 13G for the number of Class A Common Stock that are beneficially owned by each Reporting Person as of March 31, 2024 as to which there is sole or shared power to vote or direct the vote, and sole or shared power to dispose or direct the disposition.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    See Item 2.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certifications.

      

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    Page 5 of 7 

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: April 24, 2024

     

    AMBIENT IMPACT (HK) LIMITED  
         
    By: /s/ Ma King Yin  
      Ma King Yin  
      Director  
         
    FOSUN INTERNATIONAL LIMITED  
         
    By: /s/ SZE Mei Ming  
      SZE Mei Ming  
      Company Secretary  

     

    Page 6 of 7 

     

     

    EXHIBIT INDEX

     

    Exhibit No.   Description
         
    99.1   Joint Filing Agreement dated September 28, 2018 by and between Ambient Impact (HK) Limited and Fosun International Limited (incorporated by reference to Exhibit 99.1 to that certain Schedule 13G filed on September 28, 2018 by the Reporting Persons with the Securities and Exchange Commission).

     

    Page 7 of 7 

     

     

    Get the next $AMRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMRX

    DatePrice TargetRatingAnalyst
    4/17/2026$19.00Buy
    UBS
    12/9/2025$15.00Overweight
    Barclays
    6/6/2025$12.00Buy
    Goldman
    2/24/2025$9.00 → $12.00Neutral → Overweight
    Analyst
    9/6/2024$9.00Underweight → Neutral
    JP Morgan
    More analyst ratings

    $AMRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    UBS initiated coverage on Amneal Pharmaceuticals with a new price target

    UBS initiated coverage of Amneal Pharmaceuticals with a rating of Buy and set a new price target of $19.00

    4/17/26 8:10:24 AM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Amneal Pharmaceuticals with a new price target

    Barclays initiated coverage of Amneal Pharmaceuticals with a rating of Overweight and set a new price target of $15.00

    12/9/25 8:42:32 AM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on Amneal Pharmaceuticals with a new price target

    Goldman initiated coverage of Amneal Pharmaceuticals with a rating of Buy and set a new price target of $12.00

    6/6/25 8:33:10 AM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRX
    SEC Filings

    View All

    SEC Form DEFM14A filed by Amneal Pharmaceuticals Inc.

    DEFM14A - Amneal Pharmaceuticals, Inc. (0001723128) (Filer)

    6/29/26 6:02:44 AM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form PREM14A filed by Amneal Pharmaceuticals Inc.

    PREM14A - Amneal Pharmaceuticals, Inc. (0001723128) (Filer)

    6/18/26 5:00:28 PM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Amneal Pharmaceuticals Inc.

    10-Q - Amneal Pharmaceuticals, Inc. (0001723128) (Filer)

    5/7/26 4:22:32 PM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations

    Approval of iohexol injection 350 mg iodine/mL in 50 mL, 75 mL and 100 mL vials, and 300 mg iodine/mL in 50 mL vial, significantly expands Amneal’s injectable contrast portfolioPortfolio now positioned to address the majority of U.S. iohexol injection market demand across key presentationsDemonstrates Amneal’s continued leadership in complex injectables and hospital products BRIDGEWATER, N.J., July 17, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company"), today announced that it has received U.S. Food and Drug Administration (FDA) approval for additional strengths and vial presentations of iohexol injection, 350 mg iodine/mL in 50 mL, 75 mL and 1

    7/17/26 8:00:00 AM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amneal to Report Second Quarter 2026 Results on July 30, 2026

    BRIDGEWATER, N.J., July 09, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company"), today announced it will report second quarter 2026 financial results on Thursday, July 30, 2026, before market open. The Company will host an audio webcast at 8:30 a.m. ET. The financial results and live webcast will be available through the Investor Relations section of the Company's website at investors.amneal.com. Individuals may register for the webcast by clicking here. To access the call by phone, dial 1 (833) 461-5787 (U.S.) or view a list of toll-free international numbers here. The access code for is 901153095. A replay of the webcast will be available shor

    7/9/26 4:05:00 PM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations

    Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more "Good ON" time with fewer daily doses compared with immediate-release levodopa/carbidopaHopledo® is already approved and marketed in the United States as CREXONT®, providing established regulatory and commercial experience as the therapy advances toward European approvalMore than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment optionsHopledo® contains a unique formulation combining immediate-release granules and extended-release pe

    6/29/26 3:00:00 AM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Autor Deborah M. sold $450,558 worth of shares (34,819 units at $12.94), decreasing direct ownership by 27% to 93,660 units (SEC Form 4)

    4 - Amneal Pharmaceuticals, Inc. (0001723128) (Issuer)

    5/12/26 4:10:27 PM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Buchi J Kevin converted options into 34,819 shares, increasing direct ownership by 86% to 75,077 units (SEC Form 4)

    4 - Amneal Pharmaceuticals, Inc. (0001723128) (Issuer)

    5/8/26 4:29:14 PM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Autor Deborah M. converted options into 34,819 shares, increasing direct ownership by 37% to 128,479 units (SEC Form 4)

    4 - Amneal Pharmaceuticals, Inc. (0001723128) (Issuer)

    5/8/26 4:28:25 PM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Amneal Pharmaceuticals Inc.

    SC 13G/A - Amneal Pharmaceuticals, Inc. (0001723128) (Subject)

    11/14/24 4:11:34 PM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Amneal Pharmaceuticals Inc.

    SC 13D/A - Amneal Pharmaceuticals, Inc. (0001723128) (Subject)

    10/31/24 6:51:29 PM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Amneal Pharmaceuticals Inc. (Amendment)

    SC 13D/A - Amneal Pharmaceuticals, Inc. (0001723128) (Subject)

    5/13/24 4:15:28 PM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRX
    Leadership Updates

    Live Leadership Updates

    View All

    Amneal Announces $2 Million Donation to Support Patient Access to Essential Medicines During Parkinson's Awareness Month

    BRIDGEWATER, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (NASDAQ:AMRX) today announced donations totaling $2 million to multiple patient assistance foundations supporting individuals living with Parkinson's disease (PD) in recognition of Parkinson's Awareness Month. These contributions reflect Amneal's ongoing commitment to expanding access to essential medicines and supporting patient care, education, and advocacy for the Parkinson's community. Every six minutes, someone in the United States is diagnosed with Parkinson's disease, underscoring the growing impact of a condition that affects more than 10 million people worldwide. As the

    4/7/26 8:00:00 AM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600

    NEW YORK, Jan. 27, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400, S&P SmallCap 600: S&P SmallCap 600 constituent TTM Technologies Inc. (NASD: TTMI) will replace Civitas Resources Inc. (NYSE:CIVI) in the S&P MidCap 400, and Amneal Pharmaceuticals Inc. (NASD: AMRX) will replace TTM Technologies in the S&P SmallCap 600 effective prior to the opening of trading on Friday, January 30. S&P SmallCap 600 constituent SM Energy Co. (NYSE:SM) is acquiring Civitas Resources in a deal expected to be completed soon, pending final closing conditions. SM Energy will remain in the S&P SmallCap 600 post-merger.Dutch Bros Inc. (NYSE:BROS) will replace Potlatc

    1/27/26 6:02:00 PM ET
    $AEIS
    $AHR
    $AMRX
    Industrial Machinery/Components
    Technology
    Real Estate Investment Trusts
    Real Estate

    Amneal Donates $1.5 Million to Support Patients During Parkinson's Awareness Month

    Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company"), a global biopharmaceutical company, today announced donations totaling $1.5 million to multiple patient assistance foundations that support individuals living with Parkinson's disease in honor of Parkinson's Awareness Month. These contributions underscore Amneal's ongoing commitment to the Parkinson's community by supporting patient care, education, and advocacy—and helping patients and caregivers navigate the unique challenges of living with the disease. Parkinson's disease affects more than 10 million people around the world. The progressive nature of the disease, along with the cost of treatment, often places signif

    4/11/25 8:00:00 AM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRX
    Financials

    Live finance-specific insights

    View All

    Amneal to Report Second Quarter 2026 Results on July 30, 2026

    BRIDGEWATER, N.J., July 09, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company"), today announced it will report second quarter 2026 financial results on Thursday, July 30, 2026, before market open. The Company will host an audio webcast at 8:30 a.m. ET. The financial results and live webcast will be available through the Investor Relations section of the Company's website at investors.amneal.com. Individuals may register for the webcast by clicking here. To access the call by phone, dial 1 (833) 461-5787 (U.S.) or view a list of toll-free international numbers here. The access code for is 901153095. A replay of the webcast will be available shor

    7/9/26 4:05:00 PM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance

    – Acquisition Positions Amneal to Capitalize on $300B+ Global Biologics LOE Opportunity – – Transaction Accelerates Growth Profile and Diversification – – Preliminary Q1 Results Reflect Continued Growth and Raising 2026 Full Year Guidance – – Company to Host Investor Conference Call Today at 8:30 a.m. EST – BRIDGEWATER, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company"), a diversified, global biopharmaceutical leader focused on expanding access to affordable and innovative medicines, today announced that it has entered into a definitive agreement to acquire 100% of Kashiv BioSciences, LLC ("Kashiv") in a transaction w

    4/22/26 6:00:00 AM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amneal to Report First Quarter 2026 Results on May 1, 2026

    BRIDGEWATER, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company"), today announced that the Company will release its first quarter 2026 financial results on Friday, May 1, 2026, prior to market open. The Company will host an audio webcast at 8:30 a.m. ET. The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com. Individuals may register for the webcast by clicking the link here. To access the call through a conference line, dial 1 (833) 461-5787 (in the U.S.) or for a list of toll-free international numbers, visit this here. The access

    4/7/26 4:01:00 PM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care